Reduced Risk for Cardiovascular Events with Albiglutide in T2DM

October 15, 2018
Gregory M. Weiss, MD

Can albiglutide reduce the risk of cardiovascular events in T2DM patients? A new study sheds some light. 

Reference: Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018. 

Related Content:

News